81 related articles for article (PubMed ID: 23930676)
1. Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.
de Keyser CE; Becker ML; Uitterlinden AG; Hofman A; Lous JJ; Elens L; Visser LE; van Schaik RH; Stricker BH
Pharmacogenomics; 2013 Aug; 14(11):1295-304. PubMed ID: 23930676
[TBL] [Abstract][Full Text] [Related]
2. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.
Elens L; Becker ML; Haufroid V; Hofman A; Visser LE; Uitterlinden AG; Stricker BCh; van Schaik RH
Pharmacogenet Genomics; 2011 Dec; 21(12):861-6. PubMed ID: 21946898
[TBL] [Abstract][Full Text] [Related]
3. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
4. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia.
Hu M; Mak VW; Xiao Y; Tomlinson B
Pharmacogenomics; 2013 Jan; 14(1):25-34. PubMed ID: 23252946
[TBL] [Abstract][Full Text] [Related]
5. Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacogenomics; 2009 Nov; 10(11):1743-51. PubMed ID: 19891551
[TBL] [Abstract][Full Text] [Related]
6. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.
Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
Drug Metab Pers Ther; 2015 Mar; 30(1):43-8. PubMed ID: 25274942
[TBL] [Abstract][Full Text] [Related]
7. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
Clin Pharmacol Ther; 2005 Nov; 78(5):551-8. PubMed ID: 16321621
[TBL] [Abstract][Full Text] [Related]
8. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
9. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
de Keyser CE; Peters BJ; Becker ML; Visser LE; Uitterlinden AG; Klungel OH; Verstuyft C; Hofman A; Maitland-van der Zee AH; Stricker BH
Pharmacogenet Genomics; 2014 Jan; 24(1):43-51. PubMed ID: 24263182
[TBL] [Abstract][Full Text] [Related]
10. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study.
Volcik KA; Nettleton JA; Ballantyne CM; Boerwinkle E
Am J Clin Nutr; 2008 Jun; 87(6):1926-31. PubMed ID: 18541586
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
13. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
14. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
Klein K; Thomas M; Winter S; Nussler AK; Niemi M; Schwab M; Zanger UM
Clin Pharmacol Ther; 2012 Jun; 91(6):1044-52. PubMed ID: 22510778
[TBL] [Abstract][Full Text] [Related]
15. Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes.
Yilmaz-Aydogan H; Kurnaz O; Kucukhuseyin O; Akadam-Teker B; Kurt O; Eronat AP; Tekeli A; Bugra Z; Ozturk O
Gene; 2013 Jul; 523(1):20-6. PubMed ID: 23583468
[TBL] [Abstract][Full Text] [Related]
16. Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients.
Kurzawski M; Malinowski D; Dziewanowski K; Droździk M
Pharmacogenet Genomics; 2014 Aug; 24(8):397-400. PubMed ID: 24921414
[TBL] [Abstract][Full Text] [Related]
17. A genetic variant of PPARA modulates cardiovascular risk biomarkers after milk consumption.
Loria-Kohen V; Espinosa-Salinas I; Ramirez de Molina A; Casas-Agustench P; Herranz J; Molina S; Fonollá J; Olivares M; Lara-Villoslada F; Reglero G; Ordovas JM
Nutrition; 2014 Oct; 30(10):1144-50. PubMed ID: 24976416
[TBL] [Abstract][Full Text] [Related]
18. Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy.
Becker ML; Elens LL; Visser LE; Hofman A; Uitterlinden AG; van Schaik RH; Stricker BH
Pharmacogenomics J; 2013 Jun; 13(3):251-6. PubMed ID: 22186618
[TBL] [Abstract][Full Text] [Related]
19. Effect of moderate and high-dose simvastatin on asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia.
Vladimirova-Kitova LG; Deneva TI; Marinov B
Cardiovasc Ther; 2011 Oct; 29(5):340-8. PubMed ID: 20345493
[TBL] [Abstract][Full Text] [Related]
20. Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin.
Kitzmiller JP; Luzum JA; Dauki A; Krauss RM; Medina MW
Clin Transl Sci; 2017 May; 10(3):172-177. PubMed ID: 28482130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
